Completed PHASE3 INTERVENTIONAL NCT00158405

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Multicentric Randomised Controlled Trial Assessing the Efficacy of Two Strategies of Structured Treatment Interruption of Highly Active Antiretroviral Therapy (HAART) Compared With a Continuous HAART in HIV- Infected Adults in Abidjan

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections

Interventions Efavirenz (EFV) Indinavir (IDV) Lamivudine (3TC) Ritonavir (NRV) Structured Treatment Interruption Zidovudine (ZDV)

Updated 6 times since 2017 Last updated: Dec 29, 2008 Started: Dec 31, 2002 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00158405, this PHASE3 trial focuses on HIV Infections and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 6 times since 2002, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bristol-Myers Squibb
French National Agency for Research on AIDS and Viral Hepatitis

Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Abidjan, Côte d’Ivoire